Myocardial Ischemia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Myocardial Ischemia – Pipeline Review, H2 2017’, provides an overview of the Myocardial Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia

The report reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Myocardial Ischemia therapeutics and enlists all their major and minor projects

The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Angionetics Inc

Bayer AG

Cellmid Ltd

CohBar Inc

Lixte Biotechnology Holdings Inc

NoNO Inc

Omniox Inc

Pathfinder Cell Therapy Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Myocardial Ischemia - Overview 7

Myocardial Ischemia - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Myocardial Ischemia - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Myocardial Ischemia - Companies Involved in Therapeutics Development 21

Angionetics Inc 21

Bayer AG 21

Cellmid Ltd 22

CohBar Inc 22

Lixte Biotechnology Holdings Inc 22

NoNO Inc 23

Omniox Inc 23

Pathfinder Cell Therapy Inc 24

Myocardial Ischemia - Drug Profiles 25

AB-002 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

alferminogene tadenovec - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

BAY-606583 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CMK-103 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

DT-010 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Humanin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

LB-100 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

OMX-4.80 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Pathfinder Cells - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

PMC-6 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

sirolimus - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Myocardial Ischemia - Dormant Projects 47

Myocardial Ischemia - Discontinued Products 49

Myocardial Ischemia - Product Development Milestones 50

Featured News & Press Releases 50

Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease 50

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease 50

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities 51

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 53

Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City 55

Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology 55

Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention 56

Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings 56

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 57

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 58

Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy 60

Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study 60

Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease 62

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 63

Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA 64

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

List of Tables

Number of Products under Development for Myocardial Ischemia, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products under Development by Universities/Institutes, H2 2017 10

Products under Development by Companies, H2 2017 11

Products under Development by Universities/Institutes, H2 2017 12

Number of Products by Stage and Target, H2 2017 14

Number of Products by Stage and Mechanism of Action, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Myocardial Ischemia – Pipeline by Angionetics Inc, H2 2017 21

Myocardial Ischemia – Pipeline by Bayer AG, H2 2017 21

Myocardial Ischemia – Pipeline by Cellmid Ltd, H2 2017 22

Myocardial Ischemia – Pipeline by CohBar Inc, H2 2017 22

Myocardial Ischemia – Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 23

Myocardial Ischemia – Pipeline by NoNO Inc, H2 2017 23

Myocardial Ischemia – Pipeline by Omniox Inc, H2 2017 23

Myocardial Ischemia – Pipeline by Pathfinder Cell Therapy Inc, H2 2017 24

Myocardial Ischemia – Dormant Projects, H2 2017 47

Myocardial Ischemia – Dormant Projects, H2 2017 (Contd..1), H2 2017 48

Myocardial Ischemia – Discontinued Products, H2 2017 49

List of Figures

List of Figures

Number of Products under Development for Myocardial Ischemia, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products by Targets, H2 2017 13

Number of Products by Stage and Targets, H2 2017 13

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports